Epithelium removal not necessary for collagen cross-linking

Article

Corneal collagen cross-linking with riboflavin, without removing the epithelium, is both safe and effective.

Corneal collagen cross-linking with riboflavin, without removing the epithelium, is both safe and effective, according to Roberto Pinelli, ILMO, Brescia, Italy.

Dr Pinelli examined two groups of five keratoconic patients. Group A was treated monocularly without removing the epithelium and Group B was treated after epithelial removal. Custom-made riboflavin eye-drops were applied to the cornea and activated by UV-A.

Dr Pinelli noted no significant differences between the two groups postoperatively. The 30 eyes in Group A, at 18 months follow-up, showed a mean K reduction of 0.83 D, higher K reduction in the 3 mm central zone, a mean uncorrected visual acuity (UCVA) improvement of 1.3 lines, a mean best spectacle corrected visual acuity (BSCVA) and an increase in central pachymetry. Furthermore, keratoconus progression was halted in all eyes.

These results demonstrate that it is not necessary to remove the epithelium in order for riboflavin to effectively penetrate the cornea.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.